Anti-Human CD276/B7-H3 Recombinant Nanobody (SAA2193) (HV612023)

Name: Anti-Human CD276/B7-H3 Recombinant Nanobody (SAA2193)
Brand: abinScience
SKU: HV612023
Price: 126 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

20ug
50ug
100ug
1mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo

HV612023

Descripción

Anti-Human CD276/B7-H3 Nanobody (SAA2193) [SAA2193] (HV612023) is a alpaca monoclonal antibody detecting B7-H3 in ELISA. Suitable for Human.

Reactividad de especies

Human

Aplicaciones

ELISA

Especie huésped

Alpaca

Clonalidad

Monoclonal

Isotipo

VHH-6His

ID de clon

SAA2193

Objetivo

4Ig-B7-H3, B7 homolog 3, B7-H3, B7H3, CD276, CD276 antigen, Costimulatory molecule

Nivel de endotoxinas

< 10 EU/mg

Pureza

>95% as determined by SDS-PAGE.

Purificación

Protein A/G purified from cell culture supernatant.

Número de acceso

Q5ZPR3

Forma

Liquid

Buffer de almacenamiento

0.01M PBS pH 7.4.

Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.

Información de uso del producto

Aplicación	Dilución
ELISA	1:2000-1:20000

Estabilidad y almacenamiento

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Fondo

CD276 antigen (B7-H3) is a ~57 kDa protein. May participate in the regulation of T-cell-mediated immune response. May play a protective role in tumor cells by inhibiting natural-killer mediated cell lysis as well as a role of marker for detection of neuroblastoma cells. May be involved in the development of acute and chronic transplant rejection and in the regulation of lymphocytic activity at mucosal surfaces. Could also play a key role in providing the placenta and fetus with a suitable immunological environment throughout pregnancy. Both isoform 1 and isoform 2 appear to be redundant in their ability to modulate CD4 T-cell responses. CD276 is the therapeutic target of omburtamab (clinical).

Nota

For research use only.

Imágenes